Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HealthKit

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

- PMLiVE

Darzalex powers ahead with frontline myeloma approval in Europe

New approval makes Darzalex first antibody drug approved in first line

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

- PMLiVE

J&J says real-world data finds no amputation risk for Invokana

Hopes the new data will persuade regulators to ease off warnings on the franchise

- PMLiVE

The Directory and digital round-up

SOPHiA Genetics acquires IBS, Kyomed becomes KYomed INNOV and launches ePRO, Medtronic unveil diabetes app

- PMLiVE

UK, Germany back routine use of J&J’s Tremfya

The IL-23 inhibitor is currently being assessed in other EU countries

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

Janssen named ‘Pharma Company of the Year’ at business intelligence awards

Adelphi Research takes home ‘Agency of the year’ trophy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links